Jayagopal Ashwath 4

What Happened
Jayagopal Ashwath, Chief Scientific & Development Officer of Opus Genetics (IRD), received a grant of 400,000 restricted stock units (RSUs) on 2026-01-22. The grant is reported at $0.00 per share (typical for RSU awards) and is an equity compensation award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-01-22 (Form 4 filed 2026-01-26). Filing appears timely.
• Transaction type/code: Award/Grant (code A) — 400,000 RSUs.
• Reported price: $0.00 per share; total reported acquisition value $0.
• Vesting: Per footnote, RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next 16 quarters (i.e., ~4 years), subject to continued service.
• Shares owned after transaction: Not specified in the provided filing.
• No 10b5-1, tax-withholding, or late-filing flags noted in the supplied information.

Context
This is a standard executive compensation grant (RSUs). RSUs convert into actual shares only as they vest and may be subject to forfeiture if the officer leaves before vesting; the $0 grant price reflects that this is an award, not a cash purchase. Such grants are common for retaining executives and do not by themselves indicate immediate buying or selling sentiment.